TEICOPLANIN
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection-associated Diarrhea and Colitis
Conditions
Clostridium Difficile Infection-associated Diarrhea and Colitis
Trial Timeline
May 15, 2020 → Mar 10, 2021
NCT ID
NCT04003818About TEICOPLANIN
TEICOPLANIN is a approved stage product being developed by Sanofi for Clostridium Difficile Infection-associated Diarrhea and Colitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04003818. Target conditions include Clostridium Difficile Infection-associated Diarrhea and Colitis.
What happened to similar drugs?
7 of 20 similar drugs in Clostridium Difficile Infection-associated Diarrhea and Colitis were approved
Approved (7) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04003818 | Approved | Terminated |
Competing Products
20 competing products in Clostridium Difficile Infection-associated Diarrhea and Colitis